Philip Frost
Fondatore presso Primrose Therapeutics, Inc.
Profilo
Philip Frost is the founder of Primrose Therapeutics, Inc. He is currently the President of Calesca Pharmaceuticals, Inc. His former positions include being an Independent Director at YM BioSciences, Inc. from 2007 to 2012, a Director at Innovive Pharmaceuticals, Inc. in 2010, a Director at Avalon Pharmaceuticals, Inc., a Vice President-Oncology at Wyeth LLC, and the Executive VP, Chief Executive & Scientific Officer at ImClone LLC from 2005 to 2007.
He was also an Adjunct Professor-Medicine at The University of Texas M.D.
Anderson Cancer Center.
Frost received a doctorate degree from the State University of New York at Buffalo.
Posizioni attive di Philip Frost
| Società | Posizione | Inizio |
|---|---|---|
| Calesca Pharmaceuticals, Inc. | Presidente | - |
| Primrose Therapeutics, Inc. | Fondatore | 21/03/2011 |
Precedenti posizioni note di Philip Frost
| Società | Posizione | Fine |
|---|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Direttore/Membro del Consiglio | 20/11/2012 |
Innovive Pharmaceuticals, Inc.
 Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | Direttore/Membro del Consiglio | 11/10/2010 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Amministratore Delegato | 01/01/2007 |
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
Avalon Pharmaceuticals, Inc.
 Avalon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD. | Direttore/Membro del Consiglio | - |
Formazione di Philip Frost
| State University of New York at Buffalo | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | Health Technology |
| Primrose Therapeutics, Inc. | |
Avalon Pharmaceuticals, Inc.
Avalon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD. | Health Technology |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
| Calesca Pharmaceuticals, Inc. |
- Borsa valori
- Insiders
- Philip Frost
